ConductScience.org, home

Library / Trials

Lifestyle Strategies to Preserve Muscle and Reduce Cardiovascular Risk in Adults With Obesity Using GLP-1 Receptor Agonists

NCT07933393, Not applicable, Not yet recruiting, University of Florida

Trial 10

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

FieldValueSource
TitleLifestyle Strategies to Preserve Muscle and Reduce Cardiovascular Risk in Adults With Obesity Using GLP-1 Receptor AgonistsClinicalTrials.gov
NCT numberNCT07933393ClinicalTrials.gov
StatusNot yet recruitingClinicalTrials.gov
PhasesNot applicableClinicalTrials.gov
Enrollment670 participants, estimatedClinicalTrials.gov
Lead sponsorUniversity of FloridaClinicalTrials.gov
ConditionsObesity & OverweightClinicalTrials.gov
InterventionsGLP-1 Lifestyle Management Program, Enhanced Usual Care Health EducationClinicalTrials.gov
First posted2026-11-12ClinicalTrials.gov
Last updated2026-11-12ClinicalTrials.gov

Registered outcomes 8

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescriptionSource
PrimaryChange in Appendicular Lean Tissue MassBaseline to 6 monthsChange in appendicular lean tissue mass measured by dual-energy X-ray absorptiometry (DXA), expressed in kilograms (kg).ClinicalTrials.gov
SecondaryChange in Atherosclerotic Cardiovascular Disease (ASCVD) RiskBaseline to 6 months and 12 months
Change in estimated 10-year atherosclerotic cardiovascular disease risk calculated using the American Heart Association PREVENT risk equations. Clinical and laboratory variables are combined to generate a single estimated risk percentage (0-100%), with higher percentages indicating greater cardiovascular risk.
ClinicalTrials.gov
SecondaryChange in SF-36v2 Physical Component Summary ScoreBaseline to 6 months and 12 months
Change in the Physical Component Summary (PCS) score of the 36-Item Short Form Health Survey, Version 2 (SF-36v2). Higher scores indicate better physical health-related quality of life. The PCS is calculated using norm-based scoring, standardized to a mean of 50 and a standard deviation of 10 in the reference population. Higher scores indicate better physical health-related quality of life.
ClinicalTrials.gov
SecondaryChange in SF-36v2 Mental Component Summary ScoreBaseline to 6 months and 12 months
Change in the Mental Component Summary (MCS) score of the 36-Item Short Form Health Survey, Version 2 (SF-36v2). Higher scores indicate better mental health-related quality of life. The MCS is calculated using norm-based scoring, standardized to a mean of 50 and a standard deviation of 10 in the reference population. Higher scores indicate better mental health-related quality of life.
ClinicalTrials.gov
SecondaryChange in Total Hip Bone Mineral DensityBaseline to 6 months and 12 monthsChange in total hip bone mineral density measured by dual-energy X-ray absorptiometry (DXA), expressed in grams per square centimeter (g/cm²).ClinicalTrials.gov
SecondaryChange in Lumbar Spine Bone Mineral DensityBaseline to 6 months and 12 monthsChange in lumbar bone mineral density measured by dual-energy X-ray absorptiometry (DXA), expressed in grams per square centimeter (g/cm²).ClinicalTrials.gov
SecondaryChange in Body WeightBaseline to 6 months and 12 monthsChange in body weight measured using a calibrated scale, expressed in kilograms (kg).ClinicalTrials.gov
SecondaryChange in Total Lean MassBaseline to 6 months and 12 monthsChange in total lean mass measured by whole-body dual-energy X-ray absorptiometry (DXA), expressed in kilograms (kg).ClinicalTrials.gov

Outcomes 0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured asSource

Results by group 0

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnitsSource

Participant flow 0

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits countedSource

Adverse events 0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEventsSource

Adverse event totals 0

The totals the trial posted for each group.

TotalGroupAffectedAt riskSource

Papers 0

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource

Grants 0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

ProjectTitlePrincipal investigatorsOrganizationFunderFiscal yearsSource

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource

Tests 0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

TestNamed asSource

Source 5

FieldValueSource
Releasetrials-2026-11-12-0.4.0ClinicalTrials.gov
Release manifest SHA-2560f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4ClinicalTrials.gov
Registry capture2026-11-12ClinicalTrials.gov
Results copy, AACT2026-03-23ClinicalTrials.gov
NIH clinical studies file2026-11-13ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)